The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASCO 2019 | What is the role of low-dose hypomethylating agents in myeloid disorders?

Jun 4, 2019

Guillermo Garcia-Manero, MD Anderson Cancer Center,talks to the AML Global Portal (AGP) about the role of low-dose hypomethylating agents in myeloid disorders during the 2019 ASCO Annual Meeting in Chicago.

What is the role of low-dose hypomethylating agents in myeloid disorders?